

## Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features

Lefrère, Hanne; Moore, Kat; Floris, Giuseppe; Sanders, Joyce; Seignette, Iris M.; Bismeyer, Tycho; Peters, Dennis; Broeks, Annegien; Wessels, Lodewyk; More Authors

**DOI**

[10.1158/1078-0432.CCR-22-3645](https://doi.org/10.1158/1078-0432.CCR-22-3645)

**Publication date**

2023

**Document Version**

Final published version

**Published in**

Clinical cancer research : an official journal of the American Association for Cancer Research

**Citation (APA)**

Lefrère, H., Moore, K., Floris, G., Sanders, J., Seignette, I. M., Bismeyer, T., Peters, D., Broeks, A., Wessels, L., & More Authors (2023). Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(18), 3729-3743. <https://doi.org/10.1158/1078-0432.CCR-22-3645>

**Important note**

To cite this publication, please use the final published version (if applicable).  
Please check the document version above.

**Copyright**

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

**Takedown policy**

Please contact us and provide details if you believe this document breaches copyrights.  
We will remove access to the work immediately and investigate your claim.

# Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features



Hanne Lefrère<sup>1,2</sup>, Kat Moore<sup>3</sup>, Giuseppe Floris<sup>4,5,6</sup>, Joyce Sanders<sup>7</sup>, Iris M. Seignette<sup>7</sup>, Tycho Bismeyer<sup>3</sup>, Dennis Peters<sup>7</sup>, Annegien Broeks<sup>8</sup>, Erik Hooijberg<sup>7</sup>, Kristel Van Calsteren<sup>9</sup>, Patrick Neven<sup>1,6,10</sup>, Ellen Warner<sup>11</sup>, Fedro Alessandro Peccatori<sup>12</sup>, Sibylle Loibl<sup>13,14</sup>, Charlotte Maggen<sup>1,15</sup>, Sileny N. Han<sup>1,10</sup>, Katarzyna J. Jerzak<sup>11</sup>, Daniela Annibaldi<sup>1</sup>, Diether Lambrechts<sup>16,17</sup>, Karin E. de Visser<sup>18,19,20</sup>, Lodewyk Wessels<sup>3,18,21</sup>, Liesbeth Lenaerts<sup>1</sup>, and Frédéric Amant<sup>1,2,10</sup>

## ABSTRACT

**Purpose:** Patients with postpartum breast cancer diagnosed after cessation of breastfeeding (postweaning, PP-BC<sub>PW</sub>) have a particularly poor prognosis compared with patients diagnosed during lactation (PP-BC<sub>DL</sub>), or to pregnant (Pr-BC) and nulliparous (NP-BC) patients, regardless of standard prognostic characteristics. Animal studies point to a role of the involution process in stimulation of tumor growth in the mammary gland. However, in women, the molecular mechanisms that underlie this poor prognosis of patients with PP-BC<sub>PW</sub> remain vastly underexplored, due to lack of adequate patient numbers and outcome data.

**Experimental Design:** We explored whether distinct prognostic features, common to all breast cancer molecular subtypes, exist in postpartum tumor tissue. Using detailed breastfeeding data, we delineated the postweaning period in PP-BC as a surrogate for mammary gland involution and performed whole transcriptome

sequencing, immunohistochemical, and (multiplex) immunofluorescent analyses on tumor tissue of patients with PP-BC<sub>PW</sub>, PP-BC<sub>DL</sub>, Pr-BC, and NP-BC.

**Results:** We found that patients with PP-BC<sub>PW</sub> having a low expression level of an immunoglobulin gene signature, but high infiltration of plasma B cells, have an increased risk for metastasis and death. Although PP-BC<sub>PW</sub> tumor tissue was also characterized by an increase in CD8<sup>+</sup> cytotoxic T cells and reduced distance among these cell types, these parameters were not associated with differential clinical outcomes among groups.

**Conclusions:** These data point to the importance of plasma B cells in the postweaning mammary tumor microenvironment regarding the poor prognosis of PP-BC<sub>PW</sub> patients. Future prospective and in-depth research needs to further explore the role of B-cell immunobiology in this specific group of young patients with breast cancer.

## Introduction

In young women, ages 40 years or younger, breast cancer is associated with more proliferative disease, poorer prognosis, and increased mortality, making it the leading cause of cancer-related death in this age group (1, 2). Variations in the definition of pregnancy-associated breast cancer have led to conflicting results regarding the association between the exact timing of a breast cancer diagnosis in these young women and their prognosis (3, 4). When differentiating breast cancers diagnosed in the postpartum period (PP-BC) from

breast cancers diagnosed during (Pr-BC) or outside (nulliparous, NP-BC) the context of a pregnancy, we (5, 6) and others (7–12) found that patients with PP-BC diagnosed up to 5 to 10 years postpartum had an approximately twofold increased risk of metastasis and/or death. This higher metastatic rate and increased mortality could not be fully attributed to differences in tumor characteristics nor intrinsic biological subtypes (13, 14).

Although the exact etiology underlying the poor prognosis of PP-BC remains poorly understood, the postpartum remodeling of the mammary gland to its pre-pregnant state, also known as mammary gland

<sup>1</sup>Department of Oncology, Laboratory of Gynaecological Oncology, KU Leuven, Leuven, Belgium. <sup>2</sup>Department of Gynaecology, Netherlands Cancer Institute, Amsterdam, The Netherlands. <sup>3</sup>Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands. <sup>4</sup>Department of Imaging and Pathology, Unit of Translational Cell & Tissue Research, KU Leuven, Leuven, Belgium. <sup>5</sup>Department of Pathology, Unit of Translational Cell & Tissue Research, University Hospitals Leuven, Leuven, Belgium. <sup>6</sup>Multidisciplinary Breast Centre, UZ-KU Leuven Cancer Institute (LKI), University Hospitals Leuven, Leuven, Belgium. <sup>7</sup>Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands. <sup>8</sup>Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. <sup>9</sup>Department of Reproduction and regeneration, Division Women and Child, Feto-Maternal Medicine, KU Leuven, Leuven, Belgium. <sup>10</sup>Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium. <sup>11</sup>Division of Medical Oncology, Department of Medicine, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada. <sup>12</sup>Division of Gynaecological Oncology, Department of Gynaecology, IEO European Institute of Oncology IRCCS, Milan, Italy. <sup>13</sup>German Breast Group, Neu-Isenburg, Hessen, Germany. <sup>14</sup>Centre for Haematology and Oncology

Bethanien, Frankfurt, Germany. <sup>15</sup>Department of Obstetrics and Prenatal Medicine, University Hospital Brussels, Brussels, Belgium. <sup>16</sup>Center for Cancer Biology, VIB, Leuven, Belgium. <sup>17</sup>Laboratory of Translational Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium. <sup>18</sup>Onco Institute, Utrecht, The Netherlands. <sup>19</sup>Division of Tumour Biology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. <sup>20</sup>Department of Immunology, Leiden University Medical Center, Leiden, The Netherlands. <sup>21</sup>Faculty of EEMCS, Delft University of Technology, Delft, The Netherlands.

**Corresponding Author:** Frédéric Amant, Department of Obstetrics and Gynecology, KU Leuven, Herestraat 49, Leuven, 3000, Belgium. E-mail: frederic.amant@uzleuven.be

Clin Cancer Res 2023;29:3729–43

doi: 10.1158/1078-0432.CCR-22-3645

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

©2023 The Authors; Published by the American Association for Cancer Research

### Translational Relevance

Data to date indicate that postpartum breast cancer (PP-BC) is seen as a high-risk subset of breast cancer in young women. Yet, the exact etiology underlying the poor prognosis of PP-BC remains poorly understood. Molecular investigations, mainly exploring the hypothesis that the postpartum mammary gland involution process is driving poor outcomes in PP-BC, are predominantly performed in preclinical animal models. In women, no studies have specifically investigated involuting breast cancer tissue. When searching for molecular mechanisms distinct to involuting PP-BC tissue, thereby using the postweaning period (PP-BC<sub>PW</sub>) as a surrogate for mammary gland involution, we found that patients with altered immunoglobulin expression levels and increased infiltration of plasma B cells in breast tumor tissue had the poorest prognosis. Our data urge further exploration of the role of B-cell immunology in the prognosis of PP-BC, which may open novel possibilities for personalized management of these patients.

involution, is thought to contribute to the increased risk for metastasis and death. Evidence from preclinical animal models point to the activation of wound-healing-like programs, with a characteristic initial inflammatory response followed by an immunosuppressive phase (4, 15, 16). In rodent models of mammary gland involution, enhanced tumor growth and increased motility and invasion of cancer cells have been observed (17, 18), which correlated with changes in the type and proportion of immune cells in the involuting tumor immune microenvironment (TIME; ref. 19). In healthy women without breast cancer, it is thought that the remodeling phase of mammary gland involution occurs in a narrow timeframe after delivery, yet a deregulated immune profile, with similarities to microenvironments present during wound healing and tumor progression, can last up to several months or even years (20, 21). In fact, leukocytes and macrophages have been shown to persist in the postpartum gland beyond 18 months, and distinct immune signatures have been found to persist up to 10 years after delivery (21, 22). In women with PP-BC, no reports exist on studies specifically investigating postweaning cancerous breast tissue (22, 23). Molecular investigations in PP-BC tissue, focusing on women with either triple-negative or ER+ breast cancer and not considering outcome data or the lactational status of the mammary gland, found an upregulation of inflammation-associated gene signatures when compared with NP control patients (22–24). In line with these findings, enrichment in (CD8<sup>+</sup>) T cells, natural killer cells, and macrophages have been reported in the TIME of PP-BC tissue (20, 25, 26). However, information about the lactational behavior of these patients at the time of their breast cancer diagnosis and data on their clinical outcome are lacking.

To investigate whether distinct, prognostic molecular features common to all breast cancer molecular subtypes exist in postpartum tumor tissue, we collected treatment-naïve breast tumor tissue from a subset of age, grade, and molecular-subtype-matched patients with PP-BC, Pr-BC, and NP-BC from a previous large-scale retrospective cohort study, thereby ensuring that all breast cancer molecular subtypes were represented (6). In addition, we gathered detailed data on lactation behavior of patients with PP-BC, to delineate the start of the postweaning period as a surrogate for involution onset. Using unbiased transcriptome analyses, IHC and multiplex immunofluorescence (mIF) analyses, we identified immune components in the TIME of postweaning PP-BC (PP-BC<sub>PW</sub>) tissue that appear to be

correlated to the particularly poor prognosis in these patients. In particular, PP-BC<sub>PW</sub> was shown to comprise a heterogenous entity in which patients, having decreased gene expression levels of Ig and B-cell-related genes while showing an increased plasma B-cell infiltration in their tumor tissue, had the poorest prognosis. Although tumor tissue of patients with PP-BC<sub>PW</sub> was also characterized by an increased presence of CD8<sup>+</sup> T cells, this was not linked to prognostic differences.


## Materials and Methods

### Patient selection and formalin-fixed paraffin-embedded tissue collection

A total of 230 archival formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens of young women ages 25 to 40 years with primary invasive breast cancer diagnosed between January 2005 and December 2017 were collected. Patient-, therapy-, and tumor-related characteristics were collected. Patients that received neoadjuvant chemotherapy were excluded from FFPE biopsy selection (a consort diagram explaining the selection of patients and samples is given in Fig. 1; details on host- and tumor-related prognostic parameters are summarized in Supplementary Table S1). FFPE tissue sections from lumpectomy or mastectomy were collected from biopsies taken for diagnostic purposes, with the tumor zone subsequently marked by means of hematoxylin and eosin (H&E) scoring by an expert breast cancer pathologist. Depending on the correlation between a patient's cancer diagnosis and pregnancy and/or lactation history, patients were classified as (i) PP-BC<sub>PW</sub>, if diagnosed within 2 years postweaning; (ii) PP-BC<sub>DL</sub>, if diagnosed during lactation; (iii) Pr-BC, if diagnosed during pregnancy; or (iv) NP-BC, if nulliparous (Fig. 1). Patients were matched for age, grade, and surrogate molecular subtype and only included if they had follow-up for at least 20 months. ER, PR, and HER-2 status were evaluated using IHC according to ASCO/CAP guidelines (27, 28). Additional *in situ* hybridization techniques were used to confirm HER-2 gene amplification according to each participating center's guidelines. Surrogate molecular subtype was classified as luminal A-like (ER positive, HER-2 negative, grades 1 and 2), luminal B-like (ER positive, HER-2 negative, and grade 3), luminal HER-2 (ER positive, HER-2 positive, and any grade), HER-2-like (ER negative, HER-2 positive, and any grade), or triple-negative breast cancer (TNBC: ER negative, PR negative, HER-2 negative, and any grade). The study was approved by Ethics Committee Research UZ/KU Leuven (S/25470). All retrospective medical data/biospecimen studies at the respective institutes have been executed pursuant to local legislation and international standards. Patients consented to the use of their personal data and biospecimens in research. Hence, the procedures comply both with (inter)national legislative and ethical standards.

### Whole transcriptome sequencing

Total RNA from the tumor area was isolated using the High Pure FFPET RNA Isolation Kit (Roche Life Science). RNA quality (DV<sub>200</sub> values) and quantity were assessed on an Agilent 2100 Bioanalyzer using the Agilent RNA 6000 Nano Chip. Biopsies that were taken longer than 15 years ago were excluded to guarantee good RNA quality and quantity (DV<sub>200</sub> > 200 nucleotides). Using 100 ng of total RNA from each sample (DV<sub>200</sub> > 30%), libraries were prepared with the Illumina TruSeq RNA Access Library Prep Kit according to the manufacturer's protocol (Illumina). Barcoded libraries were 4-plex pooled before HiSeq4000 (Illumina) sequencing with 50-bp single-end reads at a depth of 30 million reads. FASTQ files were aligned and quantified using Salmon v0.14.2 (Salmon, RRID:SCR\_017036) with



**Figure 1.**

Flow chart depicting the number of patients with breast cancer included in this study. **A**, This study was performed on a subset of patients included in a previous study (6) and for whom FFPE tumor tissue was available. Exclusion criteria were a diagnosis >2 years postweaning, postmenopausal status, invasive cancer history, pregnancy lasting <24 weeks, and insufficient data on two or more parameters or a lack of follow-up data (< 2 years). Women who became pregnant again within 2 years after delivery were excluded. Patients that received neoadjuvant chemotherapy were also excluded for FFPE biopsy selection. A total of 230 archival FFPE tumor tissue specimens of young women with primary invasive breast cancer were collected from the University Hospitals Leuven (Belgium), the Sunnybrook Health Sciences Centre (Canada), the Dutch Cancer Institute - Antoni van Leeuwenhoek Hospital (the Netherlands), the European Institute of Oncology (Italy), and the German Breast Group (Germany). Patients were grouped based on pregnancy and lactation status. NP-BC were nulliparous patients with no history of pregnancy; Pr-BC were women diagnosed during pregnancy; PP-BC<sub>DL</sub> were patients diagnosed during lactation; PP-BC<sub>PW</sub> were women diagnosed postweaning. **B**, This chart shows the exact number of patients included per type of analysis. Power calculations indicated that at least 15 patients/group were necessary for comparison analyses (ANOVA,  $\chi^2$ , Kruskal-Wallis, Wilcoxon) and at least 40 patients/group for Cox regression analyses to have a minimum power of 70%. On the basis of this, PP-BC<sub>DL</sub> (\*) and Pr-BC (\*\*) patient groups were thus excluded from statistical testing as indicated, although they were always plotted for visualization and interpretation purposes.

the GRCh38 (release 94) reference transcriptome (29). Sequence quality and alignment metrics were assessed and collected via FastQC (v.0.11.9) and MultiQC (v1.8). Samples were excluded when they had a library size  $< 5 \times 10^6$  reads, when  $< 75\%$  of reads mapped to the reference transcriptome, or when they had  $> 5\%$  of overrepresented sequences. Technical replicates were combined using DESeq2. Each sample was subsequently assigned a PAM50 classification (R package *genefu*, v2.8.0; ref. 30). There were three samples with high incongruity between surrogate molecular subtype and mRNA receptor expression (normalized count  $> 10$ ), which were removed from further analyses.

### Identification of differentially expressed genes and pathway analyses

Read count data were processed by R packages *tximport* (v1.18.0) and analyzed by DESeq2 (DESeq, RRID:SCR\_000154, v.1.30.1). Low count filtering was applied to include only genes with a cpm of 1 in at least  $n$  of samples, where  $n$  was the smallest group of replicates ( $n = 51$  samples out of 211 samples; ref. 31). Principal component analyses (PCA) and Kruskal–Wallis rank-sum tests were performed to investigate the association of PAM50 and sequencing preparation batch on DEG (Supplementary Fig. S1). As we aimed to identify genes and pathways that are specifically affected in PP-BC<sub>PW</sub> tissue, yet are common to all breast cancer subtypes, we controlled for the identified influence of PAM50 and library preparation prep in all differentially expressed genes (DEG) analyses by including them as covariates. Pairwise comparisons (PP-BC<sub>PW</sub> vs. NP-BC, PP-BC<sub>PW</sub> vs. Pr-BC, PP-BC<sub>PW</sub> vs. PP-BC<sub>DL</sub>) and aggregate comparisons (PP-BC<sub>PW</sub> vs. rest, i.e., a combination of NP-BC, Pr-BC, and PP-BC<sub>DL</sub>) were performed. Fold changes were shrunk using Bayesian estimates from *apeglm* (32). A cut-off of absolute log<sub>2</sub>-fold change of  $\geq 0.5$  and FDR  $\leq 0.05$  was applied to select DEGs. Gene set enrichment was performed using *Flexgsea* (v1.3) with 1,000 permutations, using the hallmark, GO-BP, canonical pathway, transcription factor, and chemical-genetic perturbation gene sets from MSigDB (v7.0; ref. 33). *FlexGSEA*: Flexible Gene Set Enrichment Analysis (v1.3; Bismeyer and Kim, 2019); available from <https://doi.org/10.5281/zenodo.2616660>. The weighted Kolmogorov–Smirnov statistic was used to calculate enrichment scores. The STRING proteomic database was used to further visualize networks and interactions of proteins (34).

### Computational assessment of the cellular composition using transcriptome data

To estimate the abundance of immune cells from bulk RNA-sequencing data, the web platform for *CibersortX* was used to calculate the fractions (sample size/population size) of 22 human immune cell subsets (LM22) defined in the *CibersortX* package for each bulk RNA-sequencing sample (35). *CibersortX* was run in relative mode with batch correction (B-mode) enabled and quantile normalization disabled, with 100 permutations. A fragments-per-kilobase million (FPKM) expression matrix produced via DESeq2 was used as input. Tumors were assigned a “high” or “low” score based on the *CibersortX* fractions for each immune cell subset above or on/below the median, respectively. Tcr Receptor Utilities for Solid Tissue (TRUST) was used to analyse B-cell receptor sequences by BCR CDR3s per kilo BCR reads (CPK) in each sample (36). Complete CDR3 sequence was defined as CDR3 annotated with both V and J genes. In addition, antibody isotype abundance of immunoglobulin (Ig) heavy chains (IgA, IgD, IgG, and IgM) was determined using DEG data by adding the expression of heavy chains from the same isotype.

### IHC and mIF analysis of tissue slides

For mIF, the following antibodies were included: anti-CD3 (Thermo Fisher Scientific, Catalog No. RM-9107-S1, RRID: AB\_149924, clone SP7, 1/400 dilution, 1 hour at RT), anti-FoxP3 (Abcam, Catalog No. ab20034clone 236A/E7, 1/50 dilution, 2 hours at RT), anti-CD20 (Dako, Catalog No. M0755, clone L26, 1/500 dilution, 1 hour at RT), anti-CD27 (Abcam, Catalog No. Ab131254, clone EPR8569, 1/500 dilution, 1 hour at RT), anti-CD8 (Dako, Catalog No. M7103, clone C8/144B, 1/100 dilution, 1 hour at RT), anti-CD138 (VWR, Catalog No. VWRKILM3825-C1, clone B-A38, 1/100 dilution, 1 hour at RT), and anti-PanCK (Abcam, Catalog No. Ab27988, clone AE1/AE3, 1/100 dilution, 2 hours at RT). mIF staining was performed on a Ventana Discovery Ultra automated stainer (Ventana Medical Systems), using the Opal Polaris 7-Color Manual IHC Kit (50-Slide Kit, Akoya Biosciences, Catalog No. NEL861001KT) on a subset of 47 PP-BC<sub>PW</sub>, 11 Pr-BC, and 60 NP-BC patients with remaining FFPE tissue specimens. Slides were imaged using the Vectra Polaris automated imaging system (Akoya Biosciences). Scans were made with the MOTIF protocol. Using the InForm software version 2.5.0, the MOTIF images were unmixed into eight channels: DAPI, OPAL480, OPAL520, OPAL570, OPAL620, OPAL690, OPAL780, and Auto Fluorescence and exported to a multilayered TIFF file, which were fused with HALO software (version 3.2, Indica Labs). Two pathologists independently marked the tumor regions of interest. A differentiation was made for the intratumoral region (interacting immune cells with the tumor) and the peritumoral region (area surrounding the tumor parenchyma). To prevent variation, consecutive slides were superimposed using the image registration tool with synchronized navigation. ROI were annotated using the brush and flood annotation tools. The random forest classifier is used to distinguish between tumor and stroma within the ROI. The Indica Labs Highplex FL v4.0.2 analysis algorithm was used for analysis using AI nuclei segmentation. All annotation layers were analyzed, and both the summary data and cell object data were exported in comma-separated value files using the export manager in HALO. Human tonsil FFPE tissues with and without primary antibody were used as positive and negative controls.

To improve marker specificity, cells that appeared positive for both CD3 and CD20, CD8 and CD20, or FoxP3 and CD20, were assumed to be positive only for the marker with the highest intensity. CD138 staining was found to show specific expression on epithelial cells and in the extracellular matrix and was removed from further analyses. Every cell was assigned a single cell type based on marker positivity. For the MPIF26 panel, the decreasing priority is FoxP3<sup>+</sup>, CD3<sup>+</sup>FoxP3<sup>+</sup>, CD20<sup>+</sup>, PanCK<sup>+</sup>. For the MPIF27 panel, the decreasing priority is CD3<sup>+</sup>CD8<sup>+</sup>, CD3<sup>+</sup>CD8<sup>-</sup>, CD20<sup>+</sup>, PanCK<sup>+</sup>. Spatial statistics were calculated within the tumor area drawn by a pathologist. Patterns of cell distribution were analyzed using the following spatial point statistics: density (number of positive cells per mm<sup>2</sup> in tumor area), clustering between immune cells within a cell type, clustering between immune cells of different cell types and clustering of immune cells towards PanCK<sup>+</sup> cells (37). Clustering was calculated with the L and L-cross measures at 30  $\mu$ m, which can be understood as the average density of cells around a cell per square mm, minus the average L-measure of random Poisson patterns with the same number of cells and observation window (38). Only immune cell distribution was randomized, to avoid detecting clustering of PanCK<sup>+</sup> cells. Tumors were assigned a “high” or “low” score based on the density and clustering scores above or on/below the median, respectively.

Tumor-associated plasma cells (TAPC) and tumor-infiltrating lymphocytes (TIL) were scored on H&E whole tumor sections, based on published methods (39–41). A TAPC score 0 was given when no

plasma cells were present; a score of 1 referred to the presence of at least one plasma cell; a score of 2 referred to the presence of at least one cluster of five plasma cells; and a score of 3 referred to more than two fusing clusters of plasma cells. Tumors were then classified as “low” or “high” when the TAPC score was respectively 0 to 1 or 2 to 3. In a subsequent single-plex IHC experiment, whole tissue slides were incubated with an antibody specific for CD38 (clone E7Z8C, Catalog No. 51000S, Cell Signaling Technology, 1/40,000 dilution, 1 hour at RT), as a potential marker for plasma cells. The assessment of the slides was done with Slide Score. The CD38 score was expressed as a percentage of positive cells of the total number of stromal cells both inside and outside the tumor area (42, 43). Normal glandular tissue was not considered. Tumors were then assigned a “high” or “low” score when the percentage of the intratumoral areas occupied by cells labelled for CD38 was above or on/below the median, respectively. CD38<sup>+</sup> cells were further used as a marker for plasma B cells, supported by the positive association with TAPC score, although we acknowledge its lack of specificity. The cut-off median percentages used were compatible with accepted clinical pathologic practices. Pathologists were blinded to the clinicopathologic information.

### Statistical analyses

Differences in the distributions of the categorical characteristics were compared using  $\chi^2$  analyses. For pairwise comparisons, an overall *P* value, OR, and 95% confidence intervals (CI) were determined. Continuous variables were compared by means of one-way ANOVA, (pairwise) Wilcoxon rank-sum tests, and/or Kruskal–Wallis tests. Correlation between ranked parameters was investigated based on Kendall or Spearman correlations. Survival rates were calculated from the time of diagnosis to the time of death of any cause for overall survival (OS) and to the date of first systemic metastasis for distant recurrence-free survival (DRS). OS and DRS univariate and multivariate analyses were performed using Cox regression on TMM-log2 normalized counts and Kaplan–Meier curves (44). TMM normalization was chosen over size factor normalization to minimize outlier contribution. In the multivariate models including all patients, we adjusted for stage (accounting for tumor size and lymph node infiltration), surrogate molecular subtype, and therapy (Supplementary Table S1; Fig. 1). All statistical analyses were performed using R version 4.0.3.

### Data and materials availability

Code for all analyses is publicly available at <https://github.com/nkiccb/ppbc/>. Metadata, raw RNA-sequencing data, and spatial image data contain pseudonymized information and will be made available after completion of a data transfer agreement. Requests should be directed to F.A. ([frederic.amant@uzleuven.be](mailto:frederic.amant@uzleuven.be)).


## Results

### PP-BC<sub>PW</sub> tumors are characterized by Ig gene upregulation

We collected tumor tissue from a subset (*n* = 230) of young women with primary invasive breast cancer, who were either diagnosed within 2 years postpartum (PP-BC, *n* = 91), during pregnancy (Pr-BC, *n* = 55), or never-been-pregnant (nulliparous, NP-BC, *n* = 84) and who were previously included in a large retrospective study evaluating clinical data (published in EJC by Lefrère and colleagues 2021 (ref. 6; Fig. 1; Supplementary Fig. S1). For all patients, clinicopathologic data were available and for PP-BC patients, breastfeeding history was used to differentiate breast cancers identified during lactation (PP-BC<sub>DL</sub>, *n* = 21) from those diagnosed postweaning (PP-BC<sub>PW</sub>,

*n* = 70). We delineated the postweaning period (never breastfed or after cessation of lactation) in patients with PP-BC as a surrogate for the mammary gland involution window, which has been indicated in preclinical animal models as being important in the stimulation of tumor growth and invasion of cancer cells in the mammary gland tumor microenvironment (TME). We first evaluated whether the poor cancer outcome, as previously identified for a large clinical PP-BC<sub>PW</sub> patient cohort, was still identifiable for the patients in this selected group (6). Although we did not find statistically significant differences, patients with PP-BC<sub>PW</sub> tended to have a two- to threefold increased risk for reduced survival rates (HR, 2.3–3.1-fold) and to develop metastatic disease more often (HR, 1.6–2.4-fold) compared with patients with PP-BC<sub>DL</sub>, Pr-BC, and NP-BC, independent of differences in surrogate molecular subtype, tumor stage, and therapy characteristics [including surgery, (neo)adjuvant chemotherapy, radiotherapy, hormone therapy, and anti HER2-therapy; Supplementary Table S1 and Supplementary Fig. S2] and concurring with our previous publication (6).

To elucidate which biological mechanisms are associated with this poorer prognosis, we performed whole transcriptome sequencing analyses on tumor biopsy specimens to search for gene expression signatures that are specific to PP-BC<sub>PW</sub> while being common to all breast cancer subtypes. As exploratory principal component analyses indicated that PAM50 subtype and sequencing batch contributed strongly to the variance in gene expression (Fig. 1; Supplementary Fig. S1), we controlled for these parameters in all downstream analyses. We compared the transcriptome in breast tumor tissue from patients with PP-BC<sub>PW</sub> with the transcriptomes obtained from breast tumor samples from patients with Pr-BC, PP-BC<sub>DL</sub>, and NP-BC in a series of pairwise and groupwise comparisons (Supplementary Fig. S3). Differential expression revealed the presence of 47 genes to be differentially expressed in PP-BC<sub>PW</sub> tumor tissue when compared with all other patient groups, of which 35 were significantly upregulated (Fig. 2A; Supplementary Table S2). Upregulated genes included those involved in (mucin) glycoprotein biosynthesis processes (*MUC2*), cancer-testis antigens (*POTEC* and *POTED*), and breast cancer-related genes such as estrogen receptor 2 (*ESR2*, low expressed). Remarkably, there was a dominant cluster of Ig genes, consisting of almost half of the upregulated DEGs in PP-BC<sub>PW</sub> tumor samples (Fig. 2B). This cluster, further referred to as “Ig gene signature,” consisted of 18 genes of the Ig superfamily and was expressed to a greater extent in PP-BC<sub>PW</sub> tissue (Fig. 2C). STRING database analysis of the 47 DEGs confirmed the presence of a biological cluster of genes involved in the humoral immune response (Fig. 2D). Pathway enrichment analysis using Fisher exact testing indicated that 13 of the top 20 differentially expressed pathways in PP-BC<sub>PW</sub> were related to the humoral immune response (Supplementary Fig. S4). Gene set enrichment analyses using gene ranking from DESeq2 with sample permutation (implemented via Flexgsea) did not further identify specific immunologic pathways differentially regulated in PP-BC<sub>PW</sub> tissue. Transcription factor enrichment analyses did not identify significant differences in transcriptional regulators associated with PP-BC<sub>PW</sub> compared with PP-BC<sub>DL</sub>, Pr-BC, and NP-BC (lowest adjusted *P* value is FDR 0.56). Additional PAM50 subgroup analyses confirmed that PP-BC<sub>PW</sub>-specific Ig gene signature upregulation was not driven by a specific PAM50 subtype (Supplementary Fig. S5). When applying K-means clustering to further identify patterns within the gene expression data of the 47 DEGs, the presence of three clusters was identified, which differed in their expression levels of the Ig gene signature (Fig. 2B). We found significantly more PP-BC<sub>PW</sub> tumor samples with intermediate to



**Figure 2.** RNA expression profiling discriminates PP-BC<sub>PW</sub> ( $n = 66$ ) breast tumor tissue from tumor samples from patients with PP-BC<sub>DL</sub> ( $n = 18$ ), Pr-BC ( $n = 5$ ), and NP-BC ( $n = 76$ ). **A**, DEG analysis of all expressed genes above the minimum count threshold ( $n = 22,355$ ) revealed the presence of 47 genes with statistically significant differences in gene expression in tumor biopsy samples from patients with PP-BC<sub>PW</sub> compared with the pooled transcriptomes obtained from tumor tissues from patients with PP-BC<sub>DL</sub>, Pr-BC, and NP-BC. **B**, Counts were subjected to a variance stabilizing transformation and visualized as row Z scores. K-means clustering of the gene expression data of the 47 DEGs identified the presence of three groups showing either high, intermediate, or low expression (column clusters) of the Ig gene signature (row cluster 3). Immune protein coding genes were identified via the ImmPort database (69). (Continued on the following page.)

high (81.8%) Ig gene signature expression levels compared with PP-BC<sub>DL</sub> (44.4%), Pr-BC (58.7%), and NP-BC tissue (51.3%;  $P < 0.01$ ; **Fig. 2E**). Interestingly, the genes belonging to the Ig gene signature were not differentially expressed in PP-BC<sub>PW</sub> subgroups with less or greater than 6 months' time interval between the start of the weaning period and their breast cancer diagnosis nor between PP-BC<sub>PW</sub> subgroups with less than 1 month breastfeeding versus more than 1 month of breastfeeding prior to their diagnosis (Supplementary Fig. S6). These data indicate that the overexpression of this Ig gene signature did not differ based on the time period between the start of weaning nor on the duration of prior breastfeeding. When comparing the set of 47 PP-BC<sub>PW</sub>-specific DEGs with published gene expression signatures from normal involuting mammary gland tissue, only two genes were found to be shared (*i.e.*, *CXCL14* and *CELSR2*; refs. 45, 46). Furthermore, hierarchical clustering and Spearman correlation analyses showed that the expression levels of well-known differentially expressed milk genes in our signature (*i.e.*, *LALBA*, *CSN1S1*, *CSN3*, and *CSN1S2AP*) poorly correlated with the overexpression of genes from the Ig gene signature in PP-BC<sub>PW</sub> tumor tissues, suggesting that the increased Ig gene signature in patients with PP-BC<sub>PW</sub> is not driven by lingering milk production in normal postweaning mammary gland tissue ( $R^2 = 0.046$ ;  $R = 0.22$ ;  $P = 0.08$ ; Supplementary Fig. S7). In conclusion, we observed an upregulation of the Ig gene signature in tumor tissue of patients with PP-BC<sub>PW</sub> when compared with patients with PP-BC<sub>DL</sub>, Pr-BC, and NP-BC, which cannot be fully attributed to normal lactational or other postweaning processes.

#### Patients with PP-BC<sub>PW</sub> with low intratumor Ig gene expression levels have the highest risk for death and metastasis

We next assessed whether the general overexpression of the Ig gene signature in PP-BC<sub>PW</sub> tumor tissue was associated with patient outcome. We applied a cut-off of at least 15 patients per group for comparison analyses (ANOVA, Kruskal–Wallis, Wilcoxon tests) and 40 patients per group for inclusion in Cox regression analyses, to retain a statistical power of at least 70% (**Fig. 1**). Although no statistical significance was determined for patient groups below the cut-off value, we visualized the data from the comparison analyses to get additional insight in the distribution of the data. Patients with PP-BC<sub>PW</sub> with low Ig gene expression levels (18.2%) were found to have a significantly increased risk for death ( $P = 0.04$ ) and a nonsignificant increased risk to develop metastases ( $P = 0.078$ ) compared with Pr-BC (41.2%) and NP-BC (48.7%) patients with low Ig gene expression levels; this was not the case among patients with PP-BC<sub>PW</sub> with intermediate/high Ig gene expression levels (**Fig. 2F**; Supplementary Fig. S8). No similar association was found between Ig gene signature expression levels and prognosis, based on PAM50 status (Supplementary Fig. S9), further indicating that PAM50 is not associated with prognostic differences

based on Ig gene signature expression levels. In parallel, the RNA transcriptome data were used to investigate via univariate Cox regression whether expression of specific genes was related to differential survival or metastatic rates in patients with PP-BC<sub>PW</sub> versus the other patient groups. No genes were significantly associated with differences in survival rates among the groups. Overall, 95 genes were observed to be significantly correlated to metastasis (FDR  $< 0.05$ ). Of the 59 genes that were significantly associated with an improved outcome, 20 were upregulated Ig and B-cell related genes (Supplementary Fig. S10A; Supplementary Table S3). From these 20, there were seven genes uniquely correlated with significant increased metastatic and/or death rates when expressed at low levels, specifically in PP-BC<sub>PW</sub>, which included *CD27*, *CD40LG*, *BAFF-R*, *SH2D1A*, *IGLV1-40*, *IGHV3-64D*, and *IGKV3-7* (Supplementary Fig. S10B). Together, these data suggest that a subgroup of patients with PP-BC<sub>PW</sub>, that is, those with low Ig and B-cell–related gene expression in their breast tumor tissue, have a particular increased risk for death and metastatic disease compared with patients with Pr-BC and NP-BC as well as to patients with PP-BC<sub>PW</sub> with high Ig gene signature expression levels.


#### Increased plasma B-cell levels correlate with poor outcomes in patients with PP-BC<sub>PW</sub>

We next aimed to examine whether the altered Ig gene signature expression levels were correlated with changes in (plasma) B-cell levels in breast tumor tissue of patients with PP-BC<sub>PW</sub> and whether the presence of these cells also correlated with changes in survival rates. Exploratory CIBERSORTx analyses of the transcriptome data identified no differences in estimated fractions of naïve B cells, yet we found significantly decreased proportions of memory B cells (Wilcoxon rank-sum,  $P = 0.01$ ) and significantly increased proportions of plasma B cells (Wilcoxon,  $P < 0.001$ ) in PP-BC<sub>PW</sub> samples compared with those of patients with NP-BC, but not to patients with PP-BC<sub>DL</sub> and Pr-BC (Supplementary Figs. S11A and S11B). This was not correlated to differential outcomes when comparing patients with PP-BC<sub>PW</sub> to NP-BC or Pr-BC (Supplementary Figs. S11C and S11D).

In parallel, we aimed to evaluate these findings at the cellular level, by means of mIF, IHC analysis, and microscopic evaluation of tumor biopsy slides. We used the mIF data on coexpression of CD20, CD3, and CD8 to identify—as non-plasma B cells (further referred to as CD20<sup>+</sup> cells; **Fig. 3A**). Although CD20<sup>+</sup> cell densities were not increased (Wilcoxon,  $P = 0.10$ ; **Fig. 3B**), CD20<sup>+</sup>/CD20<sup>+</sup> clustering (normalized cellular colocalization within a fixed radius of 0.30 mm) was significantly decreased (Wilcoxon,  $P = 0.03$ ; **Fig. 3D**) in PP-BC<sub>PW</sub> compared with NP-BC tissue, yet this difference was not associated with differences in prognosis (**Fig. 3C–E**; Supplementary Figs. S12A and S12B). Furthermore, no significant differences were found in clustering of CD20<sup>+</sup> cells with tumor cells when comparing all patient groups (CD20<sup>+</sup>/PanCK<sup>+</sup>; Supplementary Fig. S13). Coexpression of

(Continued.) **C**, Relationship between Ig gene signature expression and patient group. Ig gene expression (heatmap row cluster 3) was normalized via DESeq2's size factors and summed as a single metagene per sample, displayed as a log<sub>10</sub> transformation. Ig metagene expression was increased in patients with PP-BC<sub>PW</sub> compared with patients with Pr-BC ( $P = 0.01$ ) and NP-BC ( $P < 0.01$ ).  $P$  values were determined by Wilcoxon rank-sum tests. **D**, STRING database clustering analysis of RNA expression data of these 47 DEGs generated two distinct biological clusters, either involved in the humoral immune response (green) or in protein biosynthesis (red). **E**, Bar plots indicate that the group of patients with PP-BC<sub>PW</sub> harbored the largest fraction of tumor biopsy samples with an intermediate or high gene expression level of the Ig gene signature compared to patients with PP-BC<sub>DL</sub>, Pr-BC, and NP-BC ( $\chi^2 P < 0.01$ ). **F**, PP-BC<sub>DL</sub> was excluded from survival curves due to low sample numbers delivering insufficient power (see decision tree visualized in Supplementary Fig. S1). OS analysis on patients with >20 months of follow-up revealed that patients with PP-BC<sub>PW</sub> with low expression levels ( $n = 10$ ) of the Ig gene signature had a significantly increased risk for death compared with patients with Pr-BC ( $n = 19$ ) and NP-BC ( $n = 35$ ) with low Ig gene signature expression levels (log-rank  $P = 0.04$ ). No significant difference was observed in OS in patients with PP-BC<sub>PW</sub> ( $n = 29$ ), Pr-BC ( $n = 17$ ), and NP-BC ( $n = 28$ ) with medium Ig gene signature expression levels or in patients with PP-BC<sub>PW</sub> ( $n = 16$ ), Pr-BC ( $n = 6$ ), and NP-BC ( $n = 7$ ) with high Ig gene signature expression levels (log-rank  $P = 0.16$  and  $P = 0.61$ , respectively). Patients with PP-BC<sub>DL</sub> ( $n = 18$ ) were not included in the survival analysis due to insufficient numbers for significant power. Significant  $P$  values are indicated with an asterisk (\*).





Downloaded from <http://aacrjournals.org/clinccancerres/article-pdf/29/18/3736/4363729.pdf> by guest on 29 September 2023

CD20 and CD27 was used to exploratory examine differences in naïve ( $CD20^+CD27^-$ ) and memory ( $CD20^+CD27^+$ ) B-cell populations. Contrary to CibersortX findings, tissue from patients with PP-BC<sub>PW</sub> did not display altered levels of  $CD20^+CD27^-$  nor  $CD20^+CD27^+$  cells compared with the other patient groups (Supplementary Fig. S14).


To evaluate the abundance of plasma B cells within the TIME, we resorted to assessment of tumor-associated plasma cells levels (TAPC) counting and single-plex IHC staining for CD38 in FFPE slides (Fig. 3F; Supplementary Table S4). TAPC can be readily identified in H&E tissue. They were graded based on their presence: “0” if no plasma cells were found, “1” for a few scattered plasma cells, “2” for a small cluster of five plasma cells, and “3” for a confluence of clusters of plasma cells present in the stroma surrounding the clustered tumor cells (Supplementary Fig. S15). PP-BC<sub>PW</sub> tumor samples were found to have significantly higher TAPC counts (Kendall correlation  $P = 0.02$ ; Wilcoxon  $P = 0.01$ ) compared with both Pr-BC and NP-BC samples (Fig. 3G; Supplementary Fig. S16). In patients with PP-BC<sub>PW</sub>, these high TAPC counts were found to associate with an increased risk for death ( $P = 0.03$ ) and metastasis ( $P = 0.03$ ) as opposed to patients with Pr-BC and NP-BC, in whom high counts were positively associated with improved prognosis (Fig. 3H; Supplementary Fig. S13C). In addition to TAPC assessment, intratumoral  $CD38^+$  cell densities were evaluated to further examine the presence of the plasma B-cell population within the TIME (Fig. 3I; Supplementary Table S4).  $CD38^+$  cell densities were significantly increased in PP-BC<sub>PW</sub> tumor tissue compared with NP-BC tissue ( $P < 0.01$ ; Fig. 3J). Again, patients with PP-BC<sub>PW</sub> with a high intratumoral  $CD38^+$  density had a significantly increased risk for both death ( $P = 0.02$ ) and metastasis ( $P = 0.01$ ) compared with patients with NP-BC. No such outcome differences were observed among patients with low  $CD38^+$  densities (Fig. 3K; Supplementary Fig. S13D). Although CD38 is expressed on multiple immune cell types, it has the potential to be used as a marker for plasma B cells due to its high expression on this cell type (42). As there was a positive correlation between TAPC count and  $CD38^+$  intratumoral densities in the overall population ( $R^2 = 0.11$ ;  $R = 0.33$ ;  $P < 0.01$ ; Supplementary Fig. S17),  $CD38^+$  can be interpreted as a plasma B-cell marker in our population, although caution remains warranted. Together these data indicate that, opposed to patients with Pr-BC and NP-BC, in patients with PP-BC<sub>PW</sub>, an increased infiltration of TAPCs and  $CD38^+$  cells in the TIME was correlated to a significantly elevated risk for metastasis and death.

### Patients with PP-BC<sub>PW</sub> have a skewed ratio of IgA and IgG gene expression levels in breast tumor tissue

Given the low Ig gene signature expression levels and increased presence of plasma B cells in tumor tissue of PP-BC<sub>PW</sub>, both parameters being associated with a poor prognosis in this patient group, we wondered whether changes in the antibody repertoire could explain this apparent contradiction. Further exploiting the RNA sequencing data, patients with PP-BC<sub>PW</sub> were found to have significantly increased IgA and IgD gene expression levels but decreased IgG gene expression levels compared with patients with NP-BC (Wilcoxon,  $P$  values  $< 0.01$ ; Fig. 4A). IgD, but not IgA and IgG, gene expression levels were also significantly different in tumor tissue of PP-BC<sub>PW</sub> compared with patients with Pr-BC (Wilcoxon,  $P < 0.01$ ; Fig. 4A). IgM gene expression levels did not differ between patient groups. As IgA is the main Ig found in breast milk, we compared IgA gene expression levels with differentially expressed milk genes in our signature (i.e., *LALBA*, *CSN1S1*, *CSN3*, and *CSN1S2AP*). We found a positive correlation in all patient groups, with 19% to 35% of the variation explained through a correlation between IgA and the milk signature in PP-BC<sub>DL</sub>, Pr-BC, and PP-BC<sub>PW</sub> respectively, but only 9.8% to be explained within NP-BC. This indicates that high IgA expression is, at least partially, related to the lactating and/or postweaning processes in patients with PP-BC<sub>PW</sub> ( $R^2 = 0.35$ ;  $R = 0.59$ ;  $P < 0.01$ ; Supplementary Fig. S18). Increased IgG and decreased IgA gene expression levels tended to be correlated to an increased risk for death in patients with PP-BC<sub>PW</sub>, although the difference did not reach statistical significance ( $P_{IgG} = 0.057$ ;  $P_{IgA} = 0.052$ , Fig. 4B). No significant differences related to metastasis were observed. Also, no differences in neither IgD nor IgM gene expression levels were related to patient outcome (Fig. 4B; Supplementary Fig. S19). Only within the patient with PP-BC<sub>PW</sub> group, low IgA and high IgG gene expression levels were significantly associated with high TAPC counts ( $R = -0.23$ ,  $P = 0.02$  and  $R = 0.36$ ,  $P < 0.01$ , respectively; Fig. 4C and D; Supplementary Figs. S20–S21). Likewise, a comparable negative correlation for IgA ( $R = -0.24$ ;  $P = 0.1$ ) and a positive correlation for IgG ( $R = 0.25$ ;  $P = 0.09$ ) gene expression levels with CD38 intratumoral densities in PP-BC<sub>PW</sub> was found, although these results were nonsignificant (Supplementary Fig. S22). Within PP-BC<sub>PW</sub>, we observed a significant negative correlation between IgA and IgG gene expression levels ( $R^2 = 0.40$ ;  $R = -0.63$ ;  $P < 0.01$ ; Supplementary Fig. S23), underscoring the inverse effects of IgA and IgG expression within this patient group.

### Figure 3.

Validation of B-cell presence in FFPE tumor tissue of patients with PP-BC<sub>PW</sub>, Pr-BC, and NP-BC and correlation with prognosis by means of multiplex IF (mIF) CD20<sup>+</sup> labeling, TAPC scoring, and singleplex IHC CD38 labeling. **A**, Representative image of the two designed mIF panels showing staining for CD3, CD20, CD27, FoxP3, CD8, and CD138 markers. **B**, Cell density was estimated for all patient groups and visualized as a log10 transformation with a pseudocount of 1. Significance was calculated using Wilcoxon rank-sum test (pairwise) or a Kruskal–Wallis test (between all groups).  $CD20^+CD3^-CD8^-$  cells—further described as  $CD20^+$  cells—(representing nonplasma B cells). No significant difference in  $CD20^+$  densities (number of cells/total tissue area) were observed between patients with PP-BC<sub>PW</sub> ( $n = 44$ ) and NP-BC ( $n = 58$ ; Wilcoxon,  $P = 0.10$ ). mIF patient groups below the minimum power threshold of  $n = 15$  (Pr-BC,  $n = 11$  and PP-BC<sub>DL</sub>,  $n = 7$ ) are visualized but not subjected to statistical tests (see decision tree visualized in Supplementary Fig. S1). **C**, Kaplan–Meier OS curve for all patient groups with adequate sample size and follow-up  $> 20$  months. Pr-BC and PP-BC<sub>DL</sub> were excluded from mIF survival curves due to low sample numbers delivering insufficient power (see decision tree visualized in Supplementary Fig. S1). Neither high nor low  $CD20^+$  mIF density was not significantly associated with OS between PP-BC<sub>PW</sub> and NP-BC, as determined via a log-rank test. **D**,  $CD20^+/CD20^+$  clustering (normalized cellular colocalization within a fixed radius of 0.30 mm) indicate a significantly decreased clustering in patients with PP-BC<sub>PW</sub> compared with NP-BC (Wilcoxon,  $P = 0.03$ ), whereas **(E)** no difference in survival can be observed based on  $CD20^+/CD20^+$  clustering. **F**, Representative image of a patient with PP-BC<sub>PW</sub> with high and low TAPC counts in the tumor area as evaluated in an H&E-stained FFPE slide. **G**, Patients with PP-BC<sub>PW</sub> ( $n = 66$ ) present with significantly higher TAPC counts compared with patients with Pr-BC ( $n = 51$ ) and NP-BC ( $n = 76$ ; Wilcoxon,  $P = 0.01$ ). **H**, Although no significant difference in survival rates was seen between patient groups with low TAPC scores (score “0”–“1”), patients with PP-BC<sub>PW</sub> with high TAPC scores (score “2”–“3”) were associated with a significantly increased risk for death (log-rank  $P = 0.03$ ) compared with patients with Pr-BC and NP-BC. Only PP-BC<sub>DL</sub> ( $n = 17$ ) was excluded. **I**, Representative image of  $CD38^+$  IHC staining showing high and low densities of  $CD38^+$  plasma cells of a patient with PP-BC<sub>PW</sub>. **J**, Significantly increased intratumoral  $CD38^+$  plasma cell density in the tumor area of patients with PP-BC<sub>PW</sub> ( $n = 50$ ) versus patients with NP-BC ( $n = 63$ ; Wilcoxon,  $P < 0.01$ ). **K**, Although no significant difference in survival rates was seen between patient groups with low intratumoral  $CD38^+$  densities, patients with PP-BC<sub>PW</sub> with high intratumoral  $CD38^+$  densities had a significantly increased risk for death (log-rank  $P = 0.02$ ) compared with patients with NP-BC. Significant  $P$  values are indicated with an asterisk (\*).



Finally, we could not find a significant difference in clonotype diversity between PP-BC<sub>PW</sub>, PP-BC<sub>DL</sub>, Pr-BC, and NP-BC tumor tissue as estimated with TRUST (Supplementary Fig. S24A; ref. 36), indicating no differences in immunoglobulin clonal expansion between patient groups nor any association with prognosis (Supplementary Fig. S24B).

In general, these data indicate that PP-BC<sub>PW</sub> tumor tissue is characterized with increased *IgA* and decreased *IgG* gene expression levels. These data point to the existence of a heterogeneous PP-BC<sub>PW</sub> population with an upregulated expression of the *IgG* gene and a decreased expression of *IgA* gene, correlated to increased TAPC counts, the latter being associated with a particularly poor prognosis.

#### Increased intratumoral levels of CD8<sup>+</sup> cytotoxic T cells do not have a prognostic value in patients with PP-BC<sub>PW</sub>

Next, we investigated whether the differential association between plasma B-cell presence and prognosis in patients with PP-BC<sub>PW</sub> compared with the other patient groups could be related to differences in interactions with other immune components. Histopathologic analyses of tumor biopsy slides did not identify any significant difference in the general TIL percentages between the patient groups (Fig. 5A). TIL percentages were found to positively correlate with CD4<sup>+</sup> naïve T cells ( $R = 0.29$ ;  $P = 1.5 \times 10^{-09}$ ), *Ig* gene signature levels ( $R = 0.3$ ;  $P = 5.5 \times 10^{-08}$ ), and TAPC counts ( $R = 0.28$ ;  $P = 4.2 \times 10^{-07}$ ) in all study groups (Supplementary Fig. S25). Exploratory CIBERSORTx analyses of the remaining immune cell subsets from the transcriptome data showed a significantly increased fraction of CD8<sup>+</sup> cytotoxic T cells (Kruskal–Wallis,  $P = 0.02$ ) in PP-BC<sub>PW</sub> compared with PP-BC<sub>DL</sub>, Pr-BC, and NP-BC tissues (Fig. 5B). Increased CD8<sup>+</sup> fractions seemed to associate with a poorer prognosis in patients with PP-BC<sub>PW</sub>, although this difference in OS/DRS was not statistically significant (log-rank,  $P_{OS} = 0.13$  and  $P_{DRS} = 0.11$ ; Fig. 5B; Supplementary Fig. S26A). No significant differences were observed between NP and postpartum patient groups among CIBERSORTx estimated fractions of natural killer, monocytes, macrophages, mast, nor dendritic immune cell subsets (Supplementary Fig. S27). This finding was further validated using our previously described mIF panels in which we stained for CD3<sup>+</sup>CD8<sup>+</sup> T cells, further referred to as CD8<sup>+</sup> T cells, and CD3<sup>+</sup>CD8<sup>-</sup> T cells, further referred to as CD8<sup>-</sup> T cells. mIF staining confirmed a significantly increased density of CD8<sup>+</sup> T cells (number of cells/total tissue area; Wilcoxon,  $P = 0.005$ ; Fig. 5C), yet decreased clustering of CD8<sup>+</sup>/CD8<sup>-</sup> T cells (normalized cellular colocalization within a fixed radius of 0.30  $\mu$ m; Wilcoxon,  $P = 0.02$ , Fig. 5D) in the TIME of patients with PP-BC<sub>PW</sub> compared with what was seen in patients with NP-BC. Furthermore, compared with NP-BC tissue, PP-BC<sub>PW</sub> tissue was characterized by decreased clustering between CD8<sup>+</sup>/CD8<sup>-</sup> T cells (Wilcoxon,  $P = 0.01$ ; Fig. 5E); between CD20<sup>+</sup> B cells/CD8<sup>+</sup> T cells (Wilcoxon,  $P = 0.01$ ; Fig. 5F) and between CD20<sup>+</sup> B cells/CD8<sup>-</sup> T cells (Wilcoxon,  $P = 0.001$ ;


Fig. 5G). Although, in general, high clustering between these immune cells was associated with an increased risk for death and metastasis in especially patients with PP-BC<sub>PW</sub>, these differences were not statistically significant (Fig. 5; Supplementary Fig. S26). No significant differences in clustering between CD8<sup>+</sup> T cells/PanCK<sup>+</sup> tumor cells nor CD8<sup>-</sup> T cells/PanCK<sup>+</sup> tumor cells were observed between patient groups (Supplementary Figs. S28A and S28B). Although clustering of CD8<sup>-</sup>/CD8<sup>-</sup> T cells was decreased in PP-BC<sub>PW</sub> compared with NP-BC, also no overall significant differences between patients' groups were observed (Supplementary Fig. S28C). Together, these data demonstrate that the observed differences in CD8<sup>+</sup> T-cell densities or distances to other immune cells in the TIME of patients with PP-BC<sub>PW</sub> did not correlate with differential prognosis when comparing patient groups.

## Discussion

Here, we performed a comprehensive and large-scale analysis of PP-BC tissue, obtained from patients diagnosed with different molecular breast cancer subtypes, to specifically investigate if there is a distinct molecular signature in the postweaning mammary gland, as a surrogate for the postpartum involuting microenvironment, that is associated with the typical poor prognosis of this patient group. Interestingly, we identified decreased *Ig* gene signature expression levels and an increased tumor infiltration by plasma B cells in PP-BC<sub>PW</sub> tumor tissue, being correlated with the poorest outcomes. This is the first time that an association with plasma B cells and breast cancer prognosis has been revealed in the context of PP-BC. These data may imply that plasma B cells could adopt protumoral roles in this PP-BC setting. At present, the factors defining the functional role of plasma B cells in cancer are not fully understood (42, 47, 48). Although there is much evidence regarding the significance of tumor-infiltrating T cells in breast cancer, little is known about the role of B cells and plasma B cells in breast cancer, and existing data are often conflicting (49–53). Local residing plasma B cells, typically occupying chronic inflammation sites in the TIME, have been found to produce high titers of tumor-specific antibodies that can drive antitumorigenic effects (54, 55), by promoting antibody-dependent cytotoxicity and phagocytosis (56), complement activation and enhancing antigen presentation by dendritic cells (57–60). Although antitumor effects of B cells are mainly attributed to the *IgG* isotype, the *IgA* isotype is more often associated with an immunosuppressive microenvironment in which B cells promote expansion of regulatory T cells and reduce cytolytic killing activity of T cells (55, 61). In our patient with Pr-BC and NP-BC groups, we observed such an association between high plasma B-cell densities, an upregulation of the *Ig* gene signature, increased *IgG* gene expression, decreased *IgA* gene expression levels, and improved prognosis. Although we found significant increased yet

#### Figure 4.

*Ig*-heavy subtype repertoire in transcriptome sequencing data of patients with PP-BC<sub>PW</sub> ( $n = 66$ ), PP-BC<sub>DL</sub> ( $n = 18$ ), Pr-BC ( $n = 51$ ), and NP-BC ( $n = 76$ ). Heavy-chain genes from the same antibody isotype (i.e., IGHA1 and IGHA2) were summed and subjected to TMM normalization with a log<sub>2</sub> transformation. **A**, Increased expression levels of *IgA* (Wilcoxon,  $P < 0.01$ ) and *IgD* (Wilcoxon,  $P < 0.01$ ) genes and decreased expression levels of *IgG* genes (Wilcoxon,  $P < 0.01$ ) were observed in PP-BC<sub>PW</sub> versus NP-BC breast cancer tissue. No significant differences were observed in PP-BC<sub>PW</sub> compared with neither PP-BC<sub>DL</sub> nor Pr-BC. No significant difference was observed in the *IgM* repertoire (Kruskal–Wallis,  $P = 0.50$ ) between patient groups. **B**, PP-BC<sub>DL</sub> ( $n = 7$ ) was excluded from survival curves due to low sample numbers delivering insufficient power (see decision tree in Supplementary Fig. S1). Patients with PP-BC<sub>PW</sub> with low *IgA* gene expression levels had a borderline significant poorer prognosis compared with Pr-BC and NP-BC (log-rank,  $P = 0.052$ ). No significant difference was observed between patient groups with low *IgD* (log-rank,  $P = 0.26$ ), *IgG* (log-rank,  $P = 0.98$ ), or *IgM* (log-rank,  $P = 0.15$ ) gene expression levels. Within the groups with high *IgG* gene expression levels, patients with PP-BC<sub>PW</sub> had a nonsignificant increased risk for death compared with patients with Pr-BC and NP-BC (log-rank  $P = 0.057$ ). No difference in survival were observed in patients with high *IgA*, *IgD*, or *IgM* gene expression levels (log-rank  $P$  values of respectively 0.86, 0.56, and 0.37). **C**, *IgA* gene expression levels were negatively correlated with TAPC counts in PP-BC<sub>PW</sub> (Kendall correlation,  $R = -0.23$ ,  $P = 0.02$ ), whereas *IgG* gene expression levels (**D**) were positively correlated with TAPC counts (Kendall correlation,  $R = 0.36$ ,  $P < 0.01$ ). Significant  $P$  values are indicated with an asterisk (\*).



decreased gene expression levels of respectively *IgA* and *IgG* in PP-BC<sub>PW</sub> compared with Pr-BC and NP-BC, no prognostic differences based on Ig-heavy subtype were observed between our patient cohorts. We did identify patients with PP-BC<sub>PW</sub> with high plasma B-cell infiltration, previously correlated with poorer outcomes, to be skewed towards low *IgA* and high *IgG* gene expression levels. It has been shown that, dependent on the composition of the TIME, the phenotypes of B cells present and the antibodies they produce, certain types of tumor-infiltrating (plasma) B cells can exert protumor effects (55). In the PP-BC<sub>PW</sub> setting, it might be possible that plasma B cells produce *IgG* antibodies that do not efficiently elicit T-cell responses, as has been reported for other tumor types (55, 62, 63). Another hypothesis that may explain the apparent contradictory correlation between the poor prognosis of PP-BC<sub>PW</sub>, elevated plasma B-cell frequencies, and increased *IgG* gene expression levels in PP-BC<sub>PW</sub> TIME and is that *IgG* gene expression is not B-cell derived but coming from cancer cells (47, 64, 65). Studies have shown that cancer-derived Ig share identical basic structures with B-cell-derived Ig but can have profound protumorigenic effects via different mechanisms, including promotion of tumor immune escape (66), inducing inflammation (67), and downregulation of the cytotoxic and natural killer cells (68). In contrast to B cells using the Ig transcription factor *Oct-2*, cancer cells tend to use *Oct-1*. Although no difference in DEG for *Oct-1* nor *Oct-2* were observed between study groups, high expression levels of the *Oct-1* gene were significantly related with poor prognosis in our PP-BC<sub>PW</sub> cohort ( $P = 0.01$ ). Future IHC investigations on the presence and localization of immunoglobulin (subtypes) in PP-BC<sub>PW</sub> tissue could help elucidating the cellular source of the upregulated *IgG* genes.

Apart from changes in the B-cell compartment, we also found an increased infiltration of CD8<sup>+</sup> cytotoxic T cells in PP-BC<sub>PW</sub> tumor tissue. This is in line with previous findings in biopsy tissue taken from patients with PP-BC, but for whom the diagnosis was not specifically delineated to the postweaning period or included only one specific breast cancer molecular subtype (20, 24–26). Yet, using patient outcome data, we were able to show that neither changes in cytotoxic CD8<sup>+</sup> T-cell frequencies nor differences in colocalization with other lymphocytes in the TIME were correlated to the poor prognosis of patients with PP-BC<sub>PW</sub>.

As mentioned, access to breast tumor tissue along with information on the patients' lactational behavior and cancer outcome is a unique strength of this study, which allowed us to delineate the postweaning window and investigate the correlation between molecular alterations in postweaning breast cancer tissue and the patients' prognosis. Similar findings in all surrogate molecular subtypes suggests that the role of the plasma B-cell compartment in the prognosis of PP-BC<sub>PW</sub> is a general phenomenon. As for some analyses, we lacked a sufficient number of

patients in the Pr-BC and PP-BC<sub>DL</sub> patient groups to reach significant power, future studies should focus on repeating similar analyses with higher patient numbers. Changes in Ig-heavy gene expression should be validated at the protein level. Despite initial inclusion of several Ig-heavy antibodies in our mIF panels, we were not able to optimize these panels accordingly due to a specific binding. Also, the immune milieu profiling by IHC and mIF was focused on a small subset of markers, with TAPC scoring and CD38<sup>+</sup> staining being the sole markers to identify plasma cells. Although we observed a good correlation between TAPC and CD38 positivity, CD38 is not a specific marker for plasma B cells, and results should be interpreted with caution. Future research, where possible, focusing on prospective collection of fresh samples, larger sample sizes and single-cell (spatial) approaches that focus on individual B-cell subsets, using CD19, CD21, CD23, CD24, CD80, CD86, and TLR markers, can support further characterization of the full B-cell repertoire and their exact role in the PP-BC<sub>PW</sub> TIME.

### Conclusion

We identified PP-BC as a heterogenous entity and further distinguished a subgroup of patients with PP-BC<sub>PW</sub>, characterized by changes in Ig gene expression and plasma B-cell levels, being associated with a particular poor outcome. Although we also found significant differences in presence and clustering of/with CD8<sup>+</sup> T cells in the breast tumor tissue of patients with PP-BC<sub>PW</sub>, these parameters had no prognostic value. The molecular and immunologic differences identified in this research when comparing tumor tissue from patients with PP-BC<sub>PW</sub> with that from control patients may serve as an important starting point for additional biomarker research. In particular, further in-depth characterization of the role of B cells in the intratumoral context in PP-BC, may pave the way for personalized management strategies for these patients.

### Authors' Disclosures

F.A. Peccatori reports personal fees from Roche Diagnostics, Ipsen, and Merck outside the submitted work. S. Loibl reports grants and other support from AZ, AbbVie, Amgen, DSI, Gilead, Celgene/BMS, Novartis, and Pfizer; grants from Molecular He; other support from Seagen, Sanofi, Relay, Olema, Eirgenix, Merck KG, Lilly, GSK, Pierre Fabre, Esai, MSD, and Incyte outside the submitted work; in addition, S. Loibl also has a patent for VM Scope with royalties paid, a patent for EP14153692.0 pending, a patent for EP21152186.9 pending, and a patent for EP15702464.7 pending. K.J. Jerzak reports personal fees from Amgen, AstraZeneca, Apo Biologix, Eli Lilly, Esai, Genomic Health, Gilead Sciences, Knight Therapeutics, Merck, Myriad Genetics Inc, Pfizer, Roche, Seagen, Novartis, and Viatrix; and grants from AstraZeneca, Eli Lilly, and Seagen outside the submitted work. K.E. de Visser reports grants from Roche/Genentech, Dutch Cancer Society (KWF), Dutch Research Council (NWO), Oncode Institute, and ERC outside the submitted work; and other support from Macomics. L.F. Wessels reports grants from BMS outside the submitted work. No disclosures were reported by the other authors.

### Figure 5.

Presence of TILs and clustering between CD20<sup>+</sup> naïve B cells, CD8<sup>+</sup> cytotoxic T cells, and CD8<sup>-</sup> T cells in breast tumor tissue and correlation with outcome. When applicable, patient groups below the minimum power threshold (Pr-BC,  $n = 11$  and PP-BC<sub>DL</sub>,  $n = 7$ ) are visualized but not subjected to statistical tests (see decision tree in Supplementary Fig. S1). Patient groups are also accordingly removed from the survival analyses. **A**, No statistical difference in stromal TIL infiltration was observed between PP-BC<sub>PW</sub> ( $n = 66$ ), Pr-BC ( $n = 51$ ), and NP-BC ( $n = 76$ ; Kruskal–Wallis,  $P = 0.17$ ) tumor tissue. **B**, CIBERSORTx analyses indicated a significant increase in CD8<sup>+</sup> cytotoxic T-cell fractions in PP-BC<sub>PW</sub> ( $n = 55$ ), PP-BC<sub>DL</sub> ( $n = 17$ ), Pr-BC ( $n = 42$ ), and NP-BC ( $n = 70$ ; Kruskal–Wallis,  $P = 0.01$ ) tissue. No significant prognostic differences related to CD8<sup>+</sup> CIBERSORTx fractions were observed in patients with PP-BC<sub>PW</sub> compared with patients with Pr-BC and NP-BC. **C**, Immune cell density (number of cells/total tissue area and log10 transformation) and **(D)** localized clustering (normalized cellular colocalization at a radius of 30 mm) in CD8<sup>+</sup> T cells significantly differed in PP-BC<sub>PW</sub> tissue compared with NP-BC tissue (Wilcoxon,  $P = 0.005$  and  $P = 0.02$ , respectively). The observed increased CD8<sup>+</sup> T-cell densities and decreased CD8<sup>+</sup> clustering in PP-BC<sub>PW</sub> were not associated with differences in survival between patients with PP-BC<sub>PW</sub> and NP-BC. **E**, PP-BC<sub>PW</sub> tumor tissue showed a significant decrease in clustering of CD8<sup>+</sup> with CD8<sup>-</sup> T cells (Wilcoxon,  $P = 0.02$ ) compared with NP-BC tissue. In PP-BC<sub>PW</sub> tumor tissue, there was a significant decrease in clustering of CD20<sup>+</sup> cells with **(F)** CD8<sup>+</sup> T cells and **(G)** CD8<sup>-</sup> T cells compared with NP-BC tissue (Wilcoxon,  $P = 0.01$  and  $P = 0.002$ , respectively). Clustering of these immune cell types did not correlate to prognostic differences in patients with PP-BC<sub>PW</sub> compared with patients with NP-BC. Significant  $P$  values are indicated with an asterisk (\*).

## Authors' Contributions

**H. Lefrère:** Data curation, software, formal analysis, funding acquisition, validation, investigation, visualization, methodology, writing—original draft, writing—review and editing. **K. Moore:** Data curation, software, formal analysis, validation, visualization, writing—original draft, writing—review and editing. **G. Floris:** Funding acquisition, validation, investigation, methodology, writing—review and editing. **J. Sanders:** Investigation, methodology, writing—review and editing. **I.M. Seignette:** Investigation, writing—review and editing. **T. Bismeijer:** Software, formal analysis, visualization, writing—review and editing. **D. Peters:** Investigation, writing—review and editing. **A. Broeks:** Methodology, writing—review and editing. **E. Hooijberg:** Funding acquisition, validation, methodology, writing—review and editing. **K. Van Calsteren:** Resources, writing—review and editing. **P. Neven:** Resources, writing—review and editing. **E. Warner:** Resources, writing—review and editing. **F.A. Peccatori:** Resources, writing—review and editing. **S. Loibl:** Resources, writing—review and editing. **C. Maggen:** Resources, writing—review and editing. **S.N. Han:** Resources, writing—review and editing. **K.J. Jerzak:** Resources, writing—review and editing. **D. Annibali:** Writing—review and editing. **D. Lambrechts:** Conceptualization, software, supervision, funding acquisition, methodology, writing—review and editing. **K.E. de Visser:** Funding acquisition, validation, methodology, writing—review and editing. **L. Wessels:** Software, formal analysis, supervision, funding acquisition, methodology, writing—original draft, writing—review and editing. **L. Lenaerts:** Conceptualization, supervision, funding acquisition, methodology, writing—original draft, project administration, writing—review and editing. **F. Amant:** Conceptualization, supervision, funding acquisition, methodology, writing—original draft, project administration, writing—review and editing.

## References

- Chollet-Hinton L, Anders CK, Tse CK, Bell MB, Yang YC, Carey LA, et al. Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the carolina breast cancer study: a case-control study. *Breast Cancer Res* 2016; 18:79.
- Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. *J Am Coll Surg* 2009;208:341–7.
- Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they collide. *J Mammary Gland Biol Neoplasia* 2009;14:87–98.
- Schedin P. Pregnancy-associated breast cancer and metastasis. *Nat Rev Cancer* 2006;6:281–91.
- Van den Rul N, Han SN, Van Calsteren K, Neven P, Amant F. Postpartum breast cancer behaves differently. *Facts Views Vis Obgyn* 2011;3:183–8.
- Lefrère H, Floris G, Schmidt MK, Neven P, Warner E, Cardonick E, et al. Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome. *Eur J Cancer* 2021;155:13–24.
- Callihan EB, Gao D, Jindal S, Lyons TR, Manthey E, Edgerton S, et al. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. *Breast Cancer Res Treat* 2013;138:549–59.
- Whiteman MK, Hillis SD, Curtis KM, McDonald JA, Wingo PA, Marchbanks PA. Reproductive history and mortality after breast cancer diagnosis. *Obstet Gynecol* 2004;104:146–54.
- Strasser-Weippl K, Ramchandani R, Fan L, Li J, Hurlbert M, Finkelstein D, et al. Pregnancy-associated breast cancer in women from Shanghai: risk and prognosis. *Breast Cancer Res Treat* 2015;149:255–61.
- Azim HA Jr, Santoro L, Russell-Edu W, Pentheroudakis G, Pavlidis N, Peccatori FA. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. *Cancer Treat Rev* 2012;38:834–42.
- Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. *Breast Cancer Res Treat* 2016;160:347–60.
- Shagisultanova E, Gao D, Callihan E, Parris HJ, Risendal B, Hines LM, et al. Overall survival is the lowest among young women with postpartum breast cancer. *Eur J Cancer* 2022;168:119–27.
- Thomas A, Rhoads A, Pinkerton E, Schroeder MC, Conway KM, Hundley WG, et al. Incidence and survival among young women with stage I-III breast cancer: SEER 2000–2015. *JNCI Cancer Spectr* 2019;3:pkz040.
- Lian W, Fu F, Lin Y, Lu M, Chen B, Yang P, et al. The impact of young age for prognosis by subtype in women with early breast cancer. *Sci Rep* 2017;7:11625.

## Acknowledgments

This work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme “[647047 to F. Amant].” This work was supported by the KWF kankerbestrijding, the Dutch Cancer Society “[11132 to F. Amant].” This work was supported by the Fonds Wetenschappelijk Onderzoek, the Flemish Research Foundation or “FWO” “[G0A9219N to F. Amant].” Prof. F. Amant is senior investigator for the FWO. This work was supported by the Kom op tegen Kanker (Stand up to Cancer), the Flemish Cancer Society “[3M150537 to H. Lefrère].” Prof. Giuseppe Floris is recipient of a postdoctoral mandate from KOOR in UZ-Leuven. G. Floris is recipient of a postdoctoral mandate from the Klinische onderzoeks- en opleidingsraad (KOOR) of the University Hospitals Leuven. We thank all participating patients and all (para-) medical staff involved in registering cases in the INCIP database (see [www.cancerinpregnancy.org](http://www.cancerinpregnancy.org)). We would like to acknowledge the NKI-AVL Core Facility Molecular Pathology & Biobanking (CFMPB) for supplying NKI-AVL Biobank material and lab support. We would like to thank Michel Faas for his lab and image analysis support during his student rotation period. We acknowledge institutional funding from the KWF to the Netherlands Cancer Institute.

## Note

Supplementary data for this article are available at *Clinical Cancer Research Online* (<http://clincancerres.aacrjournals.org/>).

Received November 23, 2022; revised March 23, 2023; accepted July 11, 2023; published first July 14, 2023.

- Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis. *Breast* 2013;22 Suppl2:S66–72.
- Stein T, Morris JS, Davies CR, Weber-Hall SJ, Duffy MA, Heath VJ, et al. Involvement of the mouse mammary gland is associated with an immune cascade and an acute-phase response, involving LBP, CD14 and STAT3. *Breast Cancer Res* 2004;6:R75–91.
- Schedin P, O'Brien J, Rudolph M, Stein T, Borges V. Microenvironment of the involuting mammary gland mediates mammary cancer progression. *J Mammary Gland Biol Neoplasia* 2007;12:71–82.
- Lyons TR, Borges VF, Betts CB, Guo Q, Kapoor P, Martinson HA, et al. Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. *J Clin Invest* 2014;124:3901–12.
- Hitchcock J, Hughes K, Pensa S, Lloyd-Lewis B, Watson CJ. The immune environment of the mammary gland fluctuates during post-lactational regression and correlates with tumour growth rate. *Development* 2022;149:dev200162.
- Martinson HA, Jindal S, Durand-Rougely C, Borges VF, Schedin P. Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression. *Int J Cancer* 2015;136:1803–13.
- Jindal S, Gao D, Bell P, Albrektsen G, Edgerton SM, Ambrosone CB, et al. Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling. *Breast Cancer Res* 2014;16:R31.
- Asztalos S, Pham TN, Gann PH, Hayes MK, Deaton R, Wiley EL, et al. High incidence of triple negative breast cancers following pregnancy and an associated gene expression signature. *Springerplus* 2015;4:710.
- Jindal S, Pennock ND, Sun D, Horton W, Ozaki MK, Narasimhan J, et al. Postpartum breast cancer has a distinct molecular profile that predicts poor outcomes. *Nat Commun* 2021;12:6341.
- Vohra SN, Walens A, Hamilton AM, Sherman ME, Schedin P, Nichols HB, et al. Molecular and clinical characterization of postpartum-associated breast cancer in the carolina breast cancer study phase I-III, 1993–2013. *Cancer Epidemiol Biomarkers Prev* 2022;31:561–8.
- Guo Q, Bartish M, Goncalves C, Huang F, Smith-Voudouris J, Krisna SS, et al. The MNK1/2-eIF4E axis supports immune suppression and metastasis in postpartum breast cancer. *Cancer Res* 2021;81:3876–89.
- O'Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L, et al. Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. *Am J Pathol* 2010;176:1241–55.
- Hammond ME, Hayes DF, Wolff AC, Mangu PB, Temin S. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Oncol Pract* 2010;6:195–7.

28. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline update. *J Clin Oncol* 2013; 31:3997–4013.
29. Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. *Nat Methods* 2017;14:417–9.
30. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, et al. A three-gene model to robustly identify breast cancer molecular subtypes. *J Natl Cancer Inst* 2012;104:311–25.
31. Anders S, McCarthy DJ, Chen Y, Okoniewski M, Smyth GK, Huber W, et al. Count-based differential expression analysis of RNA sequencing data using R and Bioconductor. *Nat Protoc* 2013;8:1765–86.
32. Zhu A, Ibrahim JG, Love MI. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. *Bioinformatics* 2019; 35:2084–92.
33. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;102: 15545–50.
34. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 2019;47:D607–D13.
35. Steen CB, Liu CL, Alizadeh AA, Newman AM. Profiling cell type abundance and expression in bulk tissues with CIBERSORTx. *Methods Mol Biol* 2020; 2117:135–57.
36. Song L, Cohen D, Ouyang Z, Cao Y, Hu X, Liu XS. TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. *Nat Methods* 2021;18: 627–30.
37. Baddeley A, Rubak E, Turner R. *Spatial Point Patterns: Methodology and Applications* with R. Chapman & Hall; 2016.
38. Ripley BD. Modelling spatial patterns. *J R Stat Soc Series B Stat Methodol* 1977; 39:172–92 doi.
39. Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs working group 2014. *Ann Oncol* 2015;26: 259–71.
40. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature* 2014;515:563–7.
41. Deman F, Punie K, Laenen A, Neven P, Oldenburger E, Smeets A, et al. Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes. *Breast Cancer Res Treat* 2020;184:985–98.
42. Yeong J, Lim JCT, Lee B, Li H, Chia N, Ong CCH, et al. High densities of tumor-associated plasma cells predict improved prognosis in triple negative breast cancer. *Front Immunol* 2018;9:1209.
43. Seow DYB, Yeong JPS, Lim JX, Chia N, Lim JCT, Ong CCH, et al. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. *Breast Cancer Res Treat* 2020;180: 369–77.
44. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 2010;26:139–40.
45. Lemay DG, Neville MC, Rudolph MC, Pollard KS, German JB. Gene regulatory networks in lactation: identification of global principles using bioinformatics. *BMC Syst Biol* 2007;1:56.
46. Santucci-Pereira J, Zeleniuch-Jacquotte A, Afanasyeva Y, Zhong H, Slifker M, Peri S, et al. Genomic signature of parity in the breast of premenopausal women. *Breast Cancer Res* 2019;21:46.
47. Wang J, Lin D, Peng H, Huang Y, Huang J, Gu J. Cancer-derived immunoglobulin G promotes tumor cell growth and proliferation through inducing production of reactive oxygen species. *Cell Death Dis* 2013;4:e945.
48. Pelegrina LT, Lombardi MG, Fiszman GL, Azar ME, Morgado CC, Sales ME. Immunoglobulin g from breast cancer patients regulates MCF-7 cells migration and MMP-9 activity by stimulating muscarinic acetylcholine receptors. *J Clin Immunol* 2013;33:427–35.
49. Yuen GJ, Demissie E, Pillai S. B lymphocytes and cancer: a love-hate relationship. *Trends Cancer* 2016;2:747–57.
50. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. *Cancer Res* 2008;68:5405–13.
51. Iglesias MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, et al. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. *Clin Cancer Res* 2014;20:3818–29.
52. Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. *Cell Rep* 2017;18: 248–62.
53. Mohammed ZM, Going JJ, Edwards J, Elsberger B, McMillan DC. The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer. *Br J Cancer* 2013;109:1676–84.
54. Coronella JA, Spier C, Welch M, Trevor KT, Stopeck AT, Villar H, et al. Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast. *J Immunol* 2002;169:1829–36.
55. Sharonov GV, Serebrovskaya EO, Yuzhakova DV, Britanova OV, Chudakov DM. B cells, plasma cells and antibody repertoires in the tumour microenvironment. *Nat Rev Immunol* 2020;20:294–307.
56. Gilbert AE, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs DH, et al. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. *PLoS One* 2011;6:e19330.
57. Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumor T-cell immunity. *Nature* 2015;521:99–104.
58. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. *Nat Rev Immunol* 2006;6:741–50.
59. Pimenta EM, Barnes BJ. Role of tertiary lymphoid structures (TLS) in anti-tumor immunity: potential tumor-induced cytokines/chemokines that regulate TLS formation in epithelial-derived cancers. *Cancers (Basel)* 2014;6:969–97.
60. Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. *Cancer Lett* 2013;333:222–8.
61. Stavnezer J, Kang J. The surprising discovery that TGF beta specifically induces the IgA class switch. *J Immunol* 2009;182:5–7.
62. Collins AM, Jackson KJ. A temporal model of human IgE and IgG antibody formation. *Front Immunol* 2013;4:235.
63. Harris RJ, Cheung A, Ng JCF, Laddach R, Chenoweth AM, Crescioli S, et al. Tumor-infiltrating B lymphocyte profiling identifies IgG-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer. *Cancer Res* 2021;81:4290–304.
64. Cui M, Huang J, Zhang S, Liu Q, Liao Q, Qiu X. Immunoglobulin expression in cancer cells and its critical roles in tumorigenesis. *Front Immunol* 2021;12: 613530.
65. Zhao J, Peng H, Gao J, Nong A, Hua H, Yang S, et al. Current insights into the expression and functions of tumor-derived immunoglobulins. *Cell Death Discov* 2021;7:148.
66. Wang Z, Geng Z, Shao W, Liu E, Zhang J, Tang J, et al. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells. *Cell Mol Immunol* 2020;17:1148–62.
67. Wang J, Lin D, Peng H, Shao J, Gu J. Cancer-derived immunoglobulin G promotes LPS-induced proinflammatory cytokine production via binding to TLR4 in cervical cancer cells. *Oncotarget* 2014;5:9727–43.
68. Li M, Zheng H, Duan Z, Liu H, Hu D, Bode A, et al. Promotion of cell proliferation and inhibition of ADCC by cancerous immunoglobulin expressed in cancer cell lines. *Cell Mol Immunol* 2012;9:54–61.
69. Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. *Sci Data* 2018;5:180015.